Press Release: Med Fusion : med fusion Selects N-of-One to Provide Integrated Interpretation for med fusion's New Hematologic Neoplasm Profiles

CONCORD, Mass.--(BUSINESS WIRE)--N-of-One, Inc., a market leader in clinical interpretation with clinical trial matching for molecular tests, today announced that med fusion, a Texas Oncology and The US Oncology Network preferred laboratory, has selected N-of-One to provide integrated interpretation of med fusion's new HemeSEQ profiles for AML, CLL, DLBCL and MPN diseases. MDS and Myeloid profiles are in development and will be made available later this year. Financial terms of the agreement a